Abstract
BACKGROUND. Clinical course of coronavirus disease (COVID-19) in patients infected by SARS-CoV-2 varies from the absolute absence of symptoms to the extremely severe viral pneumonias with the development of acute respiratory distress syndrome. In this context, investigation of the peculiarities of disease course in dependence of viral load (VL) is very interesting.
OBJECTIVE. The aim of this paper is to analyze the results of novel clinical studies, dedicated to VL estimation in different biological specimens and its correlation with the severity of COVID-19 clinical course.
RESULTS AND DISCUSSION. During the first months of 2020 there were published some scientific studies, which analyzed the association between VL and the severity of COVID-19 clinical course. It was established that VL was high at the beginning of the disease; in the sputum its value was higher than in throat and nasal swabs. In comparison to the mild course of COVID-19, severe course is characterized by higher VL and longer release of the virus into the environment. Apart from that, high VL is associated with the significant increase of proinflammatory cytokines’ levels, risk of disease progress and unfavorable prognosis.
CONCLUSIONS. VL can be considered a risk factor and the predictor of severe course of COVID-19. Measures, aimed at the effective decrease of VL on each stage of the disease, and the improvement of antiepidemic control must help to optimize the treatment and prevent the spread of infection.
Publisher
Communicable Diseases Intensive Care Association
Reference22 articles.
1. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. World Health Organization, 2020. Available at: https://www.who. int/dg/speeches/detail/who-director-general-sopening-remarks-at-the-media- briefing-on-covid-19-11-march-2020.
2. Wu Z., McGoogan J.M. Characteristics of and important lessons from the corona- virus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648.
3. Mawaddah A., Gendeh H.S., Lum S.G., Marina M.B. Upper respiratory tract samp- ling in COVID-19. Malays J. Pathol. 2020 Apr; 42 (1): 23-35.
4. Peeri N.C., Shrestha N., Rahman M.S., Zaki R., Tan Z., Bibi S., Baghbanzadeh M., Aghamohammadi N., Zhang W., Haque U. The SARS, MERS and novel coronavi- rus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol. 2020.
5. Yu F., Du L., Ojcius D.M., Pan C., Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak origi- nating in Wuhan, China. Microbes Infect. 2020; 22: 74-79.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. STUDY OF THE SARS-COV-2 GLOBAL DISTRIBUTION AMONG DIFFERENT ANIMAL SPECIES;Naukovì Dopovìdì Nacìonalʹnogo Unìversitetu Bìoresursiv ì Prirodokoristuvannâ Ukraïni;2024